Track what you can see: weekly photos from the same angle, notes on play interest, grooming frequency, and how the coat feels under your hand
Hyaashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Swisher SG , Ajani JA
A double-blind, placebo-controlled, multicenter study of 90 patients found that intramuscular ALC (500 mg twice daily for 14 days followed by oral ALC 1,000 mg twice daily for 42 days) produced significantly greater reduction in pain compared with placebo in the efficacy-evaluable population (P=0.022).[4] An open cohort study of 21 HIV-positive patients with established ATN treated with oral ALC 1,500 mg twice daily for up to 33 months demonstrated remarkable nerve regeneration: mean immunostaining area for small sensory fibers increased 100% in epidermis and 133% in dermis after 6 months, with neuropathic grade improving in 76% of patients.[5] However, a subsequent open-label study found that while ALC therapy coincided with improvements in subjective measures of pain, changes were not observed in objective measures of intra-epidermal nerve fiber density or mitochondrial DNA levels.[6] Context with Other Treatments: Second-line or adjunctive therapy for ATN
In this paper we are mainly interested in intracellular liver metabolism, so we take a somewhat simple view of the fates glutathione and its metabolites in the blood
Barnes PJ: Reactive oxygen species and airway inflammation
